NCT05555693 Correlation Between Postoperative Cognitive-related Adverse Reactions and Brain Metabolomic Characteristics in Elderly Patients
| NCT ID | NCT05555693 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University |
| Condition | POCD - Postoperative Cognitive Dysfunction |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-07-27 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2022-07-27 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Postoperative cognitive dysfunction (POCD) refers to the difficulties of orientation, cognition, communication, memory and abstract thinking of patients after anesthesia and surgery. And/or accompanied by the decline of the ability in social activities, such as the change of personality, social ability of language and behavior, cognitive function and life skills. POCD is a common complication of central nervous system in elderly patients after operation, with an early incidence of about 21% and a long-term incidence of about 35% . According to the current research on Alzheimer's disease (AD) and POCD in the elderly, it has been found that they have similar pathological basis and some homologous related genes. Altogether, POCD is closely related to molecular pathway neuropsychiatric diseases (such as dementia, depression and Alzheimer's disease). Researchers have come up with various hypotheses to reveal the underlying mechanisms of POCD, including neuritis, oxidative stress, autophagy disorder, synaptic dysfunction, and lack of neurotrophic support. To date, apart from evaluating with scales, CT Scan and EEG analysis, there is neither exact biomarkers for monitoring and diagnosing POCD, nor clear relationships between specific Brain Metabolomic Characteristics, EEG changes and diagnosis of POCD, so that the diagnosis of early POCD only stays in the evaluation of clinical symptoms and scales. Therefore, our study aims to provide an effective basis for early diagnosis and treatment of clinical POCD through multivariate analyses of clinical scales combined with Brain Metabolomic Characteristics, EEG analysis of patients.
Eligibility Criteria
Inclusion Criteria: * 65 years or older . * Complete the operation in our hospital * ASA classification I-II level * Agree to participate in this research and agree to sign an informed consent form Exclusion Criteria: * History of preoperative psychosis and psychotropic drug use * The subject is diagnosed with AD; * Abnormal preoperative mental scale assessment * Have a history of emergency rescue during the perioperative period * metal implants * Postoperative immobilization patients
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05555693 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying POCD - Postoperative Cognitive Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05555693 currently recruiting?
Yes, NCT05555693 is actively recruiting participants. Contact the research team at zhouren77@126.com for enrollment information.
Where is the NCT05555693 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT05555693 clinical trial?
NCT05555693 is sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University. The trial plans to enroll 200 participants.